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Irene A. Burger1,8
Abstract
Background: Positron emission tomography (PET) is increasingly applied for in vivo brown adipose tissue (BAT)
research in healthy volunteers. To limit the radiation exposure, the injected 18F-FDG tracer dose should be as low as
possible. With simultaneous PET/MR imaging, the radiation exposure due to computed tomography (CT) can be
avoided, but more importantly, the PET acquisition time can often be increased to match the more extensive
magnetic resonance (MR) imaging protocol. The potential gain in detected coincidence counts, due to the longer
acquisition time, can then be applied to decrease the injected tracer dose. The aim of this study was to investigate
the minimal 18F-FDG dose for a 10-min time-of-flight (TOF) PET/MR acquisition that would still allow accurate
quantification of supraclavicular BAT volume and activity.
Methods: Twenty datasets from 13 volunteers were retrospectively included from a prospective clinical study. PET
emission datasets were modified to simulate step-wise reductions of the original 75 MBq injected dose. The
resulting PET images were visually and quantitatively assessed and compared to a 4-min reference scan. For the
visual assessment, the image quality and artifacts were scored using a 5-point and a 3-point Likert scale. For the
quantitative analysis, image noise and artifacts, BAT metabolic activity, BAT metabolic volume (BMV), and total BAT
glycolysis (TBG) were investigated.
Results: The visual assessment showed still good image quality for the 35%, 30%, and 25% activity reconstructions
with no artifacts. Quantitatively, the background noise was similar to the reference for the 35% and 30% activity
reconstructions and the artifacts started to increase significantly in the 25% and lower activity reconstructions. There
was no significant difference in supraclavicular BAT metabolic activity, BMV, and TBG between the reference and
the 35% to 20% activity reconstructions.
Conclusions: This study indicates that when the PET acquisition time is matched to the 10-min MRI protocol, the
injected 18F-FDG tracer dose can be reduced to approximately 19 MBq (25%) while maintaining image quality and
accurate supraclavicular BAT quantification. This could decrease the effective dose from 1.4 mSv to 0.36 mSv.
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Background
Obesity and associated metabolic disorders are a fast-
growing global health problem, having a significant impact
on healthcare costs, and more importantly also on the
quality of life [1]. Intensive research over the past years has
changed the traditional view of adipose tissue from being
an inert, lipid-storing depot to a highly dynamic, endocrine
organ. The growing interest for a better understanding of
brown adipose tissue (BAT) was triggered by the discovery
of active BAT on 18F-fluoro-2-deoxy-D-glucose (18F-FDG)
positron emission tomography (PET) scans in adult oncol-
ogy patients [2].
Brown adipocytes contain, in contrast to white adipocytes,
a very high amount of mitochondria, have multilocular lipid
droplets, and contribute to thermogenesis by directly dissi-
pating chemical energy as heat [3]. This process is facilitated
by a specific channel (uncoupling protein 1, UCP1) located
on the mitochondrial membrane, which can uncouple the
respiratory chain from the regeneration of adenosine tri-
phosphate (ATP) [4].
The high glucose consumption of activated BAT leads
to a large number of studies, using 18F-FDG PET as a
surrogate marker for its metabolic activity [5–7]. Most
of these studies, looking into the prevalence and factors
that correlated with high BAT activity, were done on
retrospective data and showed that active BAT was more
commonly seen on 18F-FDG PET scans in winter than in
summer, in women than in man, and in normal weight
vs obese patients [5, 8–12].
An increasing number of prospective trials, investigating
the activity of BAT with 18F-FDG PET, were published in
the last few years [13–15], however without any accepted
standardization of the protocols [16]. Therefore, a sugges-
tion on how to image and quantify BAT activity was pub-
lished in 2016: the Brown Adipose Reporting Criteria in
Imaging Studies (BARCIST 1.0) [17]. Additionally, to de-
tailed recommendations regarding selection of volunteers,
BAT activation (cooling or pharmaceutical), image acquisi-
tion, reconstruction, and quantification, the authors also
noted that the injected dose of 18F-FDG should be as low
as possible, for statistically valid imaging, with consider-
ation for total dosage in repeat studies [17]. However, de-
creasing the injected 18F-FDG dose could lead to decreased
PET image quality, more noise, and quantification errors.
One of the key elements for good PET image quality and
reliable quantification is detecting sufficient coincidence
events. Lowering the injected tracer dose means fewer
positron-emitting radionuclides and thus less detected 511
KeV photon pairs. This count loss can to some extent be
compensated by longer PET acquisition times. Longer scan
time, however, increases discomfort and the risk of bulk mo-
tion. It also decreases efficiency as fewer scans can be per-
formed in a day. Hence, an optimum has to be determined
between injected tracer dose and PET acquisition time.
One of the advantages of a simultaneous PET/mag-
netic resonance (MR) scanner is that PET and MR
acquisitions can be acquired at the same time. This
means that the PET acquisition time can often be in-
creased to match the more extensive magnetic resonance
(MR) imaging protocol. The potential gain in detected
coincidence counts, due to the longer PET acquisition
time, can then be applied to decrease the injected tracer
dose.
With MR several biomarkers for BAT, research can be
investigated. A recent publication by Karampinos et al.
gives a nice overview of several techniques and applications
[18]. Common MR sequences often include, next to an 18-
s acquisition time MR-AC sequence for PET attenuation,
T1- and T2-weighted sequences (approximately 3min and
30 s acquisition time, respectively) for anatomical reference.
In-phase, out-of-phase, water-only, and fat-only image data-
sets are already generated by the MR-AC sequence, but
sometimes more accurate versions are needed. The iterative
decomposition with echo-asymmetry and least squares esti-
mation (IDEAL)-IQ sequence (GE Healthcare, Waukesha,
WI, USA), a three-dimensional gradient multi-echo se-
quence, for example, takes differences in T2* into account
and generates six image datasets: in-phase, out-of-
phase, water-only, fat-only, proton-density fat fraction
(PDFF), and R2*(= 1/T2*) (approximately 3min acquisition
time) [19, 20]. Other biomarkers that can be investigated
are diffusion and perfusion with, e.g., diffusion-weighted
MR imaging (DWI), intravoxel incoherent motion (IVIM)
imaging, dynamic contrast-enhanced MRI (DCE-MRI), ar-
terial spin labeling (ASL), or blood-oxygen-level-dependent
(BOLD) imaging [18]. Metabolic activities can be investi-
gated, next to PET, with, e.g., 1H/31P/13C MR spectroscopy,
although these can be more time-consuming [18].
As the commonly performed MR protocols (like T1-,
T2-, and T2*-weighted; PDFF; and, e.g., DWI) require
approximately 10 min, we defined this as the optimal
PET scan duration for PET/MR. With simultaneous
PET/MR imaging, the radiation exposure due to com-
puted tomography (CT), as applied in hybrid PET/CT
scanners, can of course also be avoided.
It was therefore the aim of our study to minimize the
radiation exposure for healthy volunteers by finding the
minimal 18F-FDG dose for a 10-min time-of-flight
(TOF) PET/MR acquisition that would still allow accur-
ate quantification of supraclavicular BAT volume and
activity.
Methods
Participants and datasets
In this retrospective study, a total of 20 18F-FDG TOF
PET/MR datasets from 13 healthy male Caucasian vol-
unteers (median age, 23 years; range, 19–28 years; me-
dian body mass index, 22.9 kg/m2; range, 18.6–25.4 kg/
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m2) were obtained from a prospective clinical study [21].
In that study, each subject received two PET/MR scans,
separated by 14 days. However, only 20 datasets were
available for retrospective reconstructions. In short, 4 h
before the PET/MR scan, all participants received 200
mg mirabegron per os, a selective β3-adrenoreceptor
agonist, to stimulate BAT activity. Two and a half hours
before the scan, the volunteers were exposed to a stan-
dardized mild cooling protocol by applying two cooling
sleeves around the subjects’ abdomen and chest, con-
nected to a medical cooling device (Hilotherm Clinic®,
Hilotherm GmbH, Germany). Next, the volunteers were
scanned using a simultaneous TOF PET/MR system
(SIGNA PET/MR, GE Healthcare, Waukesha, WI, USA),
having a PET axial field-of-view (FoV) of 25 cm and a
TOF timing resolution of 400 ps [22, 23]. After perform-
ing a partial body MR localizer scan, a 30-min dynamic
three-dimensional (3D) PET acquisition of the neck area
(one bed station) was started and 75MBq of 18F-FDG
was injected over an intravenous line. The dynamic PET
scan was followed by a static 3D PET emission partial
body scan. It consisted of three bed stations, each with a
duration of 4 min, covering an area from the head to the
upper abdomen. During PET scanning, a default 3D
dual-echo, spoiled gradient recalled echo MR sequence
was performed for PET attenuation correction (MR-
AC). Fat and water images were automatically recon-
structed from the obtained in-phase and out-of-phase
images. The PET attenuation correction algorithm uses
an atlas for the head region and a continuous fat-water-
based attenuation correction method for the other body
parts [24, 25]. Besides the MR-AC sequence, T1-, T2-,
and T2*-weighted MR imaging was performed as well as
diffusion weighted MR imaging (DWI).
PET dose reductions
In this study only, the last 10 min of the 30-min PET
frames were used for the simulated dose reductions. The
minimal dose was expected to be below 40% of the ori-
ginal dose, as the 10-min scan is 2.5 times longer than
the standard 4-min static scans used in this and other
studies [21, 26]. Therefore, every 10-min dataset was
reconstructed using seven dose reduction steps, having
approximately 35%, 30%, 25%, 20%, 15%, 10%, and 5% of
the original counts.
To do so, first, an artificial trigger signal was inserted
every second in the PET list-mode datasets using an in-
house developed Matlab script (MATLAB R2018a, Math-
Works, Natick, MA, USA). Next, the scanner’s gating
options were enabled which allowed us to select only those
counts for PET reconstruction that were detected during
the above-indicated percentage of time between each trig-
ger signal. This way, the counts are reduced on a second by
second basis, thereby simulating a corresponding lower
injected dose. It also means that normal effects like decay,
biodistribution, and possibly volunteer motion remain in-
cluded. This unlisting process was repeated seven times for
each PET list-mode dataset to generate the seven TOF PET
sinograms with approximately the previously indicated
counts, simulating a lower activity due to a reduced injected
dose.
PET reference datasets
The 4-min reference datasets applied in this research
were created using the same 30-min PET frame datasets
that were used for the 10-min reduced activity datasets.
During PET reconstruction, the start time was set to 20
min to match the start time of the reduced activity data-
sets, and the duration was set to 4 min. This means that
the “uptake” times of the reference and reduced activity
reconstructions are the same.
PET reconstructions
PET reconstructions were performed using the scanner’s
three-dimensional ordered subset expectation maximization
(3D-OSEM) based reconstruction algorithm for TOF PET
data (VUE Point FX, GE Healthcare, Waukesha, WI, USA).
PET reconstructions included all standard corrections
like decay, scatter, random, dead time, attenuation,
normalization, and the detector response. The number
of subsets was 28 and the number of iterations was 2,
the reconstruction diameter was 60 cm, and the image
grid was 256 × 256 with 2.34 × 2.34 × 2.78 mm3 vox-
els. All OSEM reconstructions were post-filtered in
image space using an in-plane Gaussian convolution
kernel with a full-width-at-half-maximum of 5.0 mm,
followed by a standard axial filter with a three-slice
kernel using relative weights of 1:4:1.
Image analysis
All images were analyzed on a dedicated workstation
(Advantage Workstation 4.6, GE Healthcare), which
allowed images to be viewed side-by-side as well as in
fused mode. PET images were visually examined and
scored in consensus by an experienced nuclear medicine
physician and a dual trained experienced nuclear medi-
cine physician and radiologist. The image quality was
scored using a 5-point Likert scale (1, non-diagnostic
image quality to 5, excellent image quality) and image
artifacts were scored using a 3-point scale (0, no arti-
facts; 1, insignificant artifacts; 2, significant artifacts).
For the quantitative analysis, the standardized uptake
values (SUL) were normalized using the lean body mass
(LBM) [17, 27]. Cubic 16.6cm3 volumes of interest
(VOIs) were drawn bilateral in a homogeneous part of
the infraspinatus muscle and propagated to all other re-
constructions with different activities of the same scan
(Additional file 1: Figure S1). Maximum SUL (SULmax),
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mean SUL (SULmean), and the standard deviation
(SULstd) were obtained from each VOI. To assess the
image background noise, the coefficient of variation
(SULcov = SULstd/SULmean) was calculated.
VOIs were also drawn around artifacts using the work-
station autocontour tool. Only artifacts having a minimal
SUL of 2.0 g/ml on the 5% activity reconstructions were
included as these are expected to affect the reporting of
BAT. The 5% activity reconstructions were chosen as
those have the highest noise.
The effect of dose reduction on BAT metabolic activity,
BAT metabolic volume (BMV), and total BAT glycolysis
(TBG; counterpart to the normally used PET-metric “total
lesion glycolysis TLG”) was also investigated [8]. For this,
VOIs were drawn bilateral around supraclavicular BAT
and SULmax and SULmean were obtained. BMV was de-
fined as the sum of all voxel volumes within the suspected
BAT region where SUL > 1.2 g/ml. The TBG was de-
fined as the product of the BMV and its correspond-
ing SULmea n[17].
Percentage difference (%diff) parameters (X) were cal-
culated using the 4-min datasets as reference: %diff =
(Xy% − Xref%)/Xref% × 100, where y is any of the recon-
structions in the range 5–35%.
Statistical analysis
Statistical analysis was performed using Prism 7 (GraphPad
Software Inc., San Diego, California, USA). Differences in
the visual and quantitative parameters were assessed using
the Friedman test followed by Dunn’s test. Results were
considered statistically significant when p < 0.05.
Results
The 10-min PET acquisitions with 100% activity had a
median “total counts” of 111 × 106 (range 73–127 ×
106). The 10-min 35% and 5% activity reconstructions
have therefore approximately 37 × 106 and 5.3 × 106
counts, respectively. Representative examples of 35% to
5% activity reconstructions showing supraclavicular BAT
(blue arrows) are presented in Fig. 1. The axial images
clearly show a decreasing image quality and an increas-
ing amount of noise and artifacts (red arrows) with de-
creasing activity.
Visual assessment
The visual assessment showed that the reference and the
35%, 30%, and 25% activity reconstructions have good
image quality (Fig. 2a) and no artifacts (Fig. 2b). Although
the 20% activity reconstructions have a statistically
Fig. 1 Representative dataset showing the supraclavicular BAT on MR and on PET reconstructed images with decreasing activity. a Axial MRI
“water” image. b–h Axial TOF PET images reconstructed with 35%, 30%, 25%, 20%, 15%, 10%, and 5% of the original counts, thereby simulating
corresponding lower doses. Blue arrows indicate supraclavicular BAT, and red arrows indicate increasing artifacts with decreasing activity
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significant reduction (p = 0.02) in image quality compared
to the reference, the image quality was still acceptable with
no artifacts. The 15%, 10%, and 5% activity reconstructions
have a significantly lower (p < 0.01) image quality. More-
over, the 10% and 5% activity reconstructions also suffer
from a significant increase (both p < 0.01) in artifacts and
are therefore not recommended.
Quantitative assessment for background and artifacts
The SULmax, SULstd, and SULcov, obtained from VOIs in
the homogeneous part of the infraspinatus muscle, increase
with decreasing activity (Fig. 3 and Additional file 1:
Table S1). There was no significant difference in back-
ground SULmax between the reference and the 35%,
30%, and 25% activity reconstructions. The 20% and
lower activity reconstructions started to be significantly
different from the reference (all p < 0.01). The back-
ground SULmean was significantly higher (p = 0.02 for
35% and 30%, p < 0.01 for 25–5%) in all reduced activity
reconstructions, compared to the reference. There was no
significant difference in background SULstd between the
reference and the 35% and 30% reconstructions. The 25%
Fig. 2 The image quality and artifact score for the reference and multiple simulated activities. The image quality score (a) shows that the 4-min
reference reconstruction (4 m) and the reconstructions with 35%, 30%, and 25% of the original activity have a good image quality (green). The
20% reconstructions have a somewhat lower quality (orange). The artifact score (b) shows that reconstructions with 15%, 10%, and 5% activity
have increasing artifacts (red). Results are reported as mean ± SD
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Fig. 3 (See legend on next page.)
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and lower reconstructions were all significantly different
to the reference (all p < 0.01). The background noise
(SULcov) was previously defined as the ration between
SULstd and SULmean. As the SULmean is approximately
stable over the reduced activity range, the SULcov has
similar results as the SULstd. This means that from a
quantitative perspective, the noise started to increase at
the 25% and lower activity reconstructions (all p < 0.01).
There was no significant difference in artifact SULmax
or SULmean between the reference and the 35% and 30%
reconstructions (Additional file 1: Table S2). Artifact
SULmax or SULmean started to increase at the 25% and
lower activity reconstructions (all p < 0.01)
Quantitative assessment of supraclavicular BAT
For supraclavicular BAT SULmax, only the 5% activity re-
constructions have a significantly higher value compared
to the reference (p < 0.01) (Fig. 4 and Additional file 1:
Table S3). There was no significant difference in supra-
clavicular BAT SULmean between the reference and the
reduced activity reconstructions. There is no significant
difference in supraclavicular BAT BMV and TBG be-
tween the reference and the 35%, 30%, 25%, and 20%
activity reconstructions. The 15%, 10%, and 5% activity
reconstructions have increasing differences compared to
the reference (p = 0.02, p < 0.01, p < 0.01, respectively,
for both BMV and TBG).
Combining the information from the visual assess-
ment, the quantitative assessment of the background
noise and artifacts, and the quantitative assessment of
supraclavicular BAT, we can see that the lowest possible
dose would be 25% of the original dose. Although the
artifacts and the background noise of the 25% activity
reconstruction were significantly higher in the quantita-
tive analysis, it was visually still evaluated as having good
image quality.
Discussion
Limiting the radiation exposure for volunteers in BAT
studies using 18F-FDG PET is especially important when
performing repeated scans and/or scanning of young in-
dividuals. Using a PET/MR instead of a PET/CT already
(See figure on previous page.)
Fig. 3 The measured background and artifact SUL values for the reference and multiple simulated activities. The SULmax, SULmean, SULstd, and
SULcov of the background VOIs are shown in a–d, respectively. The SULmax and SULmean of the artifact VOIs are shown in e and f. The horizontal
axis indicates the 4-min reference (4 m) and decreasing activity (x%) reconstructions. Results are reported as median ± interquartile range. An
asterisk indicates a significant difference with the reference. For the 5% activity, 2 data points in the SULmax graph (a) and 1 data point in the
SULstd graph (c) are outside the shown range
Fig. 4 Supraclavicular BAT values for multiple simulated activities. The graphs show the SULmax (a), SULmean (b), BAT metabolic volume (BMV) (c),
and total BAT glycolysis (TBG) (d) percentage difference (%diff.) values in relation to the corresponding 4-min reference scan. Results are reported
as median ± interquartile range. An asterisk indicates a significant difference with the reference
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lowers the radiation exposure due to the absence of
exposure to X-rays. Another important factor for the
radiation exposure is the injected 18F-FDG radiotracer
dose. The recently published criteria (BARCIST 1.0)
recognize this and recommend “using a dose as low as
possible for statistically valid imaging, with consideration
for total dosage in repeat studies” [17].
Overall, our study showed that with the 10-min PET
frames, the injected dose can be reduced to 19MBq
(25%, approximately 28 × 106 counts) compared to the
already established dose of 75MBq for 4 min scans,
without a significant change in supraclavicular BAT
metabolic volume and activity. Quantitatively, the back-
ground noise and artifacts increased, but these were not
considered relevant in the visual assessment. An injected
tracer dose of 19MBq corresponds to an effective dose of
only 0.36mSv. As a comparison, commonly applied doses
for BAT investigations in (healthy) adults range between
74MBq and 444MBq for PET/CT [12, 13, 15, 28] and
PET/MR [29, 30].
With recent technical developments like the introduc-
tion of silicon photomultiplier (SiPM) based photodetec-
tors in PET, the sensitivity and TOF resolution improved
considerably. The benefits of these new systems often
include improved image quality, higher resolution, more
accurate quantifications, higher signal-to-noise ratios,
and/or shorter scan times. These technical improvements
can, on the other hand, also be used to reduce the injected
radiotracer dose and thereby the radiation exposure for
patients or healthy volunteers. Especially when scanning
healthy, often young volunteers for research when there is
no direct benefit for the participants, the injected dose
should be kept as low as possible.
Recently published BAT studies already show that sub-
jects are currently given a relatively low 75–80MBq 18F-
FDG dose for a PET scan resulting in an effective dose of
approximately 1.4 mSv. When combined with a low-dose
CT for attenuation correction and anatomical reference,
this would result in a total effective dose of approximately
3.6 mSv [26]. However, with the current study, we indicate
that significant reductions in radiation exposure are still
possible while maintaining image quality when using
PET/MR where the PET scan could efficiently be com-
bined with multiparametric MRI.
It should be noted that the presented results depend
on the detected number of coincidence counts. There-
fore, higher doses are recommended for less sensitive
PET scanners, shorter acquisition protocols, or, e.g.,
obese participants.
The current BARCIST guidelines recommend an uptake
time of 60min. This is based on previous experience with
18F-FDG in oncological imaging as the optimal uptake
time for BAT research was not investigated before. For
comparison reasons, it is best to use the same uptake time
in all BAT research. In our research, we used a simulated
uptake time of 20min for both the reference and the
reduced activity datasets.
A PET scanner detects prompt coincidences, which
consist of true (what we want), scatter and random coin-
cidences. At low activities, the detector response is
approximately linear with increasing activity. At higher
activities, detector saturation effects can start to paralyze
the system and reduce performance such that the count
rate is no longer linear with increasing activity. At low
activities and in the normal clinical range, the true and
scatter coincidences scale roughly linear with the activity
(within limits), while the randoms scale more like a
quadratic function (actual curves can be found in [31]).
In a real low-dose PET scan, the amount of randoms is
therefore likely lower than in our simulated low-dose
PET. Hence, our simulated low-dose scans may some-
what underestimate the image quality.
A potential limitation of our study is that it included
only male volunteers. Further studies should be performed
to investigate the effect of dose reduction in female volun-
teers. To validate the results, future BAT studies could
stepwise lower the injected dose.
Conclusions
This study indicates that when the PET acquisition time is
matched to a 10-min MRI protocol in simultaneous PET/
MR, the injected 18F-FDG tracer dose can be reduced to
approximately 19MBq (25%) while maintaining image
quality and accurate supraclavicular BAT quantification.
This means for the participants, a decreased effective dose
is from 1.4mSv to 0.36mSv.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13550-020-0592-8.
Additional file 1: Figure S1. Examples of VOIs. (A) A coronal PET image
showing two VOIs containing BAT, (B) a coronal fused PET/MR image
showing the BAT, (C) an axial PET image showing two VOIs containing
BAT, (D) an axial fused PET/MR image showing the BAT, (E) an axial fused
PET/MR image showing VOIs for background measurements, (F) an axial
5% activity PET image showing a VOI containing an artifact, fused with
Dixon based water (G) and fat (H) MR images. The colorbars indicate the
SUL range (0-8 g/ml and 0-4 g/ml). Table S1. Background quantification.
Table S2. Artifact quantification. Table S3. BAT quantification
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deviation of SUL; SUV: Standardized uptake value; TBG: Total BAT glycolysis;
TOF: Time-of-flight; UCP1: Uncoupling protein 1; VOI: Volume of interest;
X: Parameter
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